These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30883567)

  • 1. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation.
    Chan YH; Lee KT; Kao YW; Huang CY; Chen YL; Hang SC; Chu PH
    PLoS One; 2019; 14(3):e0213517. PubMed ID: 30883567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
    Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
    J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Jenkins A; Li B; Mardekian J; Terayama Y
    Open Heart; 2020; 7(1):e001232. PubMed ID: 32341789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.
    Carmo J; Ferreira J; Costa F; Carmo P; Cavaco D; Carvalho S; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Oct; 244():196-201. PubMed ID: 28679480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes in a Warfarin-Treated Population With Atrial Fibrillation.
    Björck F; Renlund H; Lip GY; Wester P; Svensson PJ; Själander A
    JAMA Cardiol; 2016 May; 1(2):172-80. PubMed ID: 27437888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.
    Chan YH; Lee HF; Li PR; Liu JR; Chao TF; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2020 May; 19(1):63. PubMed ID: 32404168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Supranormal Renal Function.
    Lee SR; Choi EK; Han KD; Jung JH; Cha MJ; Oh S; Lip GYH
    Stroke; 2019 Jun; 50(6):1480-1489. PubMed ID: 31084339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Asian Patients With Atrial Fibrillation.
    Cha MJ; Choi EK; Han KD; Lee SR; Lim WH; Oh S; Lip GYH
    Stroke; 2017 Nov; 48(11):3040-3048. PubMed ID: 28974629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic, Bleeding, and Mortality Risks of Rivaroxaban and Dabigatran in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; Kuo CT; Yeh YH; Chang SH; Wu LS; Lee HF; Tu HT; See LC
    J Am Coll Cardiol; 2016 Sep; 68(13):1389-1401. PubMed ID: 27659460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis.
    Vestergaard AS; Skjøth F; Larsen TB; Ehlers LH
    PLoS One; 2017; 12(11):e0188482. PubMed ID: 29155884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: A Systematic Review and Meta-Analysis.
    Pan KL; Singer DE; Ovbiagele B; Wu YL; Ahmed MA; Lee M
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28720644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes in Atrial Fibrillation Patients With a History of Cancer Treated With Non-Vitamin K Antagonist Oral Anticoagulants: A Nationwide Cohort Study.
    Chan YH; Chao TF; Lee HF; Chen SW; Li PR; Liu JR; Wu LS; Chang SH; Yeh YH; Kuo CT; See LC; Lip GYH
    Stroke; 2021 Oct; 52(10):3132-3141. PubMed ID: 34233467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention.
    Hirano T; Kaneko H; Mishina S; Wang F; Morita S
    J Stroke Cerebrovasc Dis; 2017 Oct; 26(10):2102-2110. PubMed ID: 28532651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin.
    Frederiksen AS; Albertsen AE; Christesen AMS; Vinter N; Frost L; Møller DS
    Europace; 2018 Jul; 20(7):1078-1085. PubMed ID: 28655151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of acute kidney injury in Asians treated with apixaban, rivaroxaban, dabigatran, or warfarin for non-valvular atrial fibrillation: A nationwide cohort study in Taiwan.
    Chan YH; Yeh YH; Hsieh MY; Chang CY; Tu HT; Chang SH; See LC; Kuo CF; Kuo CT
    Int J Cardiol; 2018 Aug; 265():83-89. PubMed ID: 29885705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of non-vitamin K antagonist oral anticoagulants vs. warfarin in Japanese patients with atrial fibrillation – meta-analysis.
    Senoo K; Lau YC; Dzeshka M; Lane D; Okumura K; Lip GY
    Circ J; 2015; 79(2):339-45. PubMed ID: 25501801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with hypertrophic cardiomyopathy with non-valvular atrial fibrillation.
    Lin Y; Xiong H; Su J; Lin J; Zhou Q; Lin M; Zhao W; Peng F
    Heart Vessels; 2022 Jul; 37(7):1224-1231. PubMed ID: 35041061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis Evaluating the Efficacy and Safety of Low-Intensity Warfarin for Patients >65 Years of Age With Non-Valvular Atrial Fibrillation.
    Kang F; Ma Y; Cai A; Cheng X; Liu P; Kuang J; Mai Z; Mai W
    Am J Cardiol; 2021 Mar; 142():74-82. PubMed ID: 33307015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.